Next for Trodelvy: small-cell lung cancer
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
A triple-negative breast cancer face-off
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
